Pacira BioSciences, Inc.

NasdaqGS:PCRX

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💻 Telehealth

Location

United States

Market Cap

USD 1.12 B

Share Price

USD 24.23

Avg Daily Volume

899,133

Change (1 day)

0.33%

Change (1 year)

-13.46%

Change (YTD)

28.61%

Pacira BioSciences, Inc. Short-Term Debt for the year ending December 31, 2024: USD 210.66 M

Pacira BioSciences, Inc. Short-Term Debt is USD 210.66 M for the year ending December 31, 2024, a 1,107.79% change year over year. Short-term debt are debt obligations that are due within one year.

Pacira BioSciences, Inc. Short-Term Debt for the year ending December 31, 2023 was USD 17.44 M, a -66.39% change year over year.
Pacira BioSciences, Inc. Short-Term Debt for the year ending December 31, 2022 was USD 51.89 M, a -86.44% change year over year.
Pacira BioSciences, Inc. Short-Term Debt for the year ending December 31, 2021 was USD 382.59 M, a 143.58% change year over year.
Pacira BioSciences, Inc. Short-Term Debt for the year ending December 31, 2020 was USD 157.07 M, a 1,491.42% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Short-Term Debt	Long-Term Debt	Total Liabilities	Shareholders' Equity

NasdaqGS: PCRX

Pacira BioSciences, Inc.

CEO	Mr. Frank D. Lee
IPO Date	Feb. 3, 2011
Location	United States
Headquarters	5401 West Kennedy Boulevard
Employees	788
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💻 Telehealth

Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.